Tag: Gilead Sciences

Clinical Trials News Oncology

Gilead’s Trodelvy Shows Significant Promise in Treating Aggressive Breast Cancer

Gilead

Results from the ASCENT-03 study reveal that Trodelvy (sacituzumab govitecan-hziy) significantly enhances outcomes for patients with metastatic triple-negative breast cancer. The drug lowered the risk of disease progression or death by 38% and provided a longer duration of response compared to chemotherapy. This positions Trodelvy as a potential new standard of care for this aggressive form of breast cancer, offering hope to a patient population with limited treatment options.

Oncology News

ESMO 2025 Preview: Roche, Lilly, AbbVie, and Gilead to Present Latest Oncology Data

ESMO_2025

Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.

Business Healthcare & Pharmaceuticals News

Gilead Sciences Reports Strong Q2 2025 Results, Raises Full-Year Guidance

Gilead

Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.

Clinical Trials Healthcare & Pharmaceuticals News

Gilead Unveils Promising New Data on Twice-Yearly HIV Prevention Drug Lenacapavir

Gilead

A key takeaway from the presentation is the strong preference for the twice-yearly injection over daily oral medication among trial participants. Over 75% of those surveyed expressed a preference for the injectable option, citing increased confidence in their protection against HIV and a lower risk of missing a dose.